ATR vs IOVA
AptarGroup vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | ATR | IOVA |
|---|
| AI Score |
69
|
67
|
| Price |
$134.62
|
$6.49
|
| P/E Ratio |
24.06×
|
-9.27×
|
| ROE |
14.7%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.3%
|
116.3%
|
| Debt / Equity |
0.54×
|
0.06×
|
| Dividend Yield |
1.4%
|
0.0%
|
| RSI (14) |
48.2
|
79.2
|
| Beta |
0.382
|
0.701
|
| Expected Upside |
+1.6%
|
—
|
AI Committee View
Current Innellis committee reasoning for ATR versus IOVA.
ATR leads by 2 points.
ATR scores 69/100 (Buy) versus IOVA at 67/100 (Buy).
ATR Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical